Difficulty: Medium
Average Score: 71%
Practice
In patients with chronic granulomatous disease which of the following agents increases the synthesis of tumor necrosis factor, leading to activation of phagocytosis?
Correct answer
B
Rationale
In patients with chronic granulomatous disease (CGD), the correct agent that increases the synthesis of tumor necrosis factor, leading to the activation of phagocytosis is Interferon gamma (Option B). Interferon gamma plays a crucial role in activating macrophages and enhancing their ability to phagocytize pathogens, which can be beneficial in patients with CGD who have impaired phagocytic function due to defective NADPH oxidase.
Option A, Aldesleukin, is a recombinant interleukin-2 that primarily stimulates T-cell proliferation and activation, not phagocytosis. Option C, Filgrastim, is a granulocyte colony-stimulating factor that primarily stimulates the production and mobilization of neutrophils, which are not the primary cells involved in phagocytosis in CGD. Option D, Infliximab, is a tumor necrosis factor-alpha inhibitor and would not increase the synthesis of tumor necrosis factor as required in this scenario.
In an educational context, understanding the specific mechanisms of action of immunomodulatory agents is crucial for healthcare professionals, especially when managing patients with immunodeficiencies like CGD. Knowing the appropriate agents that can enhance phagocytic activity in these patients is essential for providing effective treatment and improving outcomes.
Option A, Aldesleukin, is a recombinant interleukin-2 that primarily stimulates T-cell proliferation and activation, not phagocytosis. Option C, Filgrastim, is a granulocyte colony-stimulating factor that primarily stimulates the production and mobilization of neutrophils, which are not the primary cells involved in phagocytosis in CGD. Option D, Infliximab, is a tumor necrosis factor-alpha inhibitor and would not increase the synthesis of tumor necrosis factor as required in this scenario.
In an educational context, understanding the specific mechanisms of action of immunomodulatory agents is crucial for healthcare professionals, especially when managing patients with immunodeficiencies like CGD. Knowing the appropriate agents that can enhance phagocytic activity in these patients is essential for providing effective treatment and improving outcomes.